



# ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

Ref:Sec/SA/Jun/2018

13<sup>th</sup> August 2018

Mr. Anish Kumar  
Assistant Vice President - Listing  
Metropolitan Stock Exchange of India Ltd  
4th Floor, Vibgyor Towers, Plot No. C 62,  
G Block, Opp. Trident Hotel,  
Bandra Kurla Complex, Bandra (E),  
MUMBAI – 400 098

Dear Sir,

**Sub: Unaudited Financial Results for the quarter ended 30<sup>th</sup> June 2018**  
**Ref: Circular No.MSE/LIST/5903/2018 dated 1.1.2018**  
**Symbol: AFDIL, Series: BE**

We refer to our letter dated 3<sup>rd</sup> August 2018 informing you of our Board Meeting that is scheduled today. The Meeting of the Board of Directors commenced at 3.30pm and concluded at 4.15pm. The Board approved unaudited financial results for the quarter ended 30<sup>th</sup> June 2018.

We are enclosing a copy of the Unaudited Financial Results for the quarter ended 30<sup>th</sup> June 2018, which were taken on record at the meeting of the Directors of the Company held today at Bangalore and the Limited Review Report, for your information.

Please take the above information on record.

Thanking you,

Yours faithfully,  
for Anglo-French Drugs & Industries Ltd.

**B. Subbarayalu**  
**GM – Regulatory Affairs & Secretarial**

Encl: A/a

BS:kg

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

REGD. OFF: 41, 3rd CROSS, SSI AREA, V BLOCK, RAJAJINAGAR, BANGALORE - 560 010

CIN: L24230KA1923PLC010205

WEBSITE: www.afdil.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER WHICH ENDED ON 30TH JUNE 2018

(Rs in Lacs, except No of equity shares & Earning per share)

PARTICULARS	STANDALONE			
	3 months ended (30/06/2018) (Un- Audited)	3 months ended (31/03/2018) (Audited)	3 months ended (30/06/2017) (Un-Audited)	Year ended (31/03/2018) (Audited)
<b>1. Income</b>				
(a) Revenue from operations	3,709	3,115	1,876	11,141
(b) Other Income	25	57	12	95
<b>Total Income</b>	<b>3,734</b>	<b>3,172</b>	<b>1,888</b>	<b>11,236</b>
<b>2. Expenses</b>				
(a) Cost of Material Consumed	1,197	1,091	676	4,113
(b) Purchase of Stock in Trade	767	650	392	2,312
(c) Changes in Inventories of Finished goods, work in progress & Stock in Trade	143	(284)	81	(138)
(d) Employee Benefits Expenses	597	602	590	2,386
(e) Finance costs	162	128	88	429
(f) Depreciation and Amortisation Expense	45	45	48	179
(g) Other Expenses	826	1,007	866	3,243
<b>Total Expenses</b>	<b>3,737</b>	<b>3,239</b>	<b>2,741</b>	<b>12,524</b>
<b>3. Profit(+)/Loss(-) before Tax (1-2)</b>	<b>(3)</b>	<b>(67)</b>	<b>(853)</b>	<b>(1,288)</b>
<b>4. Tax Expenses</b>				
i) Current Tax	1	-	-	-
ii) Deferred tax	-	(166)	-	(167)
<b>5. Profit(+)/Loss(-) for the period (3-4)</b>	<b>(4)</b>	<b>99</b>	<b>(853)</b>	<b>(1,121)</b>
<b>6. Other Comprehensive Income</b>				
(i) Items that will not be reclassified to profit & Loss	4	31	(6)	17
(ii) Income tax on items that will not be reclassified to profit or loss	-	-	-	(1)
<b>Total Other Comprehensive Income</b>	<b>4</b>	<b>31</b>	<b>(6)</b>	<b>16</b>
<b>7. Total Comprehensive Income (5+6)</b>	<b>-</b>	<b>130</b>	<b>(859)</b>	<b>(1,105)</b>
<b>8. Paid up equity share capital (Face value of Rs. 10 each)</b>	<b>116</b>	<b>116</b>	<b>116</b>	<b>116</b>
<b>Reserves excluding revaluation reserve</b>				<b>470</b>
<b>9. Earnings/(Loss) Per Share (Face value of Rs. 10 each)</b>				
a) Basic	-0.02	8.52	-73.85	-96.43
b) Diluted	-0.02	8.52	-73.85	-96.43

NOTES:

1) These financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.



- 2) The Company has adopted Ind AS 115 in respect of Right of Return from distributor point of view. Under the new standard, revenue has not been recognized for goods expected to be returned and a liability has been recognized for expected refunds to customers. Corresponding cost of sales are decreased and recovery right asset is created. Application of this standard resulted into reduction in profit amounting to Rs. 5 lacs. Prior period information has not been restated.
- 3) The Company has no reportable segments other than Pharmaceuticals division as per Ind AS.
- 4) Figures for the quarter ended 31st March 2018 are the balancing figures between audited figures for the full Financial Year upto 31st March 2018 and the published figures upto 31st December 2017 which were subject to Limited Review.
- 5) Financial results were approved at the meeting of the Board of Directors held on 13-08-2018.
- 6) Earnings per Share are not annualised except for the year ended 31st March 2018.
- 7) The figures in respect of previous period have been regrouped/recast wherever necessary.

ANGLO-FRENCH DRUGS & INDUSTRIES LTD

  
ABHAY KANORIA

CHAIRMAN & MANAGING DIRECTOR

PLACE: BENGALURU  
DATE: 13-08-2018



## Limited Review Report

**REVIEW REPORT TO  
THE BOARD OF DIRECTORS OF  
Anglo-French Drugs & Industries Limited**

We have reviewed the accompanying statement of unaudited standalone Ind AS financial results of **Anglo-French Drugs & Industries Limited** (the 'Company') for the quarter ended June 30th, 2018 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based upon our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies, have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.



The unaudited financial results for the quarter ended June 30, 2017 included in the Statement, are based on the previously issued results of the Company prepared in accordance with the Indian Accounting Standards as per Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Those unaudited financial results were reviewed by the predecessor auditor, whose limited review report dated September 12, 2017 expressed an unmodified conclusion on those unaudited financial results.

Our report is not modified in respect of this matter.

For KAMG & ASSOCIATES

Chartered Accountants

Firm Registration No. 311027E



A handwritten signature in black ink, appearing to read "S Ganesh".

S Ganesh

(Partner)

Place : Bengaluru

Date: 13-08-2018

Membership No. 232115